Skip to content

Kimberly-Clark KMB Capitalized research costs

Capitalized research costs at other companies

Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$39.94M-11.2%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$5.17M-73.7%
Angi Inc. logo
Angi Inc.ANGI
$2.94M-89.9%
Exagen Inc. logo
Exagen Inc.XGN
$1.89M-35.6%
Kadant logo
KadantKAI
$3.85M-17.8%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$132.84M+102%

Other financials

Income statement

See full
Revenue$4.2B+2.7%
Gross profit$1.5B+1.7%
Operating income$753.0M+19.3%
Net income$665.0M+17.3%
EPS (diluted)$2.00+17.6%

Balance sheet

See full
Cash & equivalents$542.0M-1.6%
Total debt$7.1B-2.2%
Total equity$1.8B+63.1%
Total assets$17.2B+5.4%

Cash flow

See full
Operating cash flow$745.0M+128%
CapEx$424.0M+108%
Free cash flow$321.0M+161%

Valuation

See full
Market cap$36.44B-9.5%
Enterprise value$42.98B-8.4%
P/E17.2×+0.6×
P/S2.2×-0.2×

Profitability

See full
Gross margin35.9%-1.0pp
Operating margin14.9%-0.9pp
Net margin12.8%-2.1pp
FCF margin11.1%-3.4pp

Returns & leverage

See full
Return on equity146.3%-83.5pp
Debt / equity3.9×-2.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by Kimberly-Clark in its filing.

Tagged under the XBRL concept kmb:DeferredTaxAssetsCapitalizedResearchCosts.

The official record: Kimberly-Clark’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kimberly-Clark's capitalized research costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kimberly-Clark's capitalized research costs?
Kimberly-Clark (KMB) reported capitalized research costs of $204M in Q4 2025.
How has Kimberly-Clark's capitalized research costs changed year-over-year?
Kimberly-Clark's capitalized research costs decreased by 25.0% year-over-year, from $272M to $204M.
What does capitalized research costs mean?
This represents the portion of research and development expenditures that have been capitalized as an asset rather than expensed immediately. It reflects the tax basis of these costs which are expected to provide future economic benefits through tax deductions. This metric is critical for understanding how a company manages its R&D investment strategy for tax purposes.